Par & Intellipharmaceutics Expand ADHD Pact

The two pharma firms have added the development and commercialization of additional strengths of generic Focalin XR for the U.S. market to their existing agreement.

Canadian specialty pharmaceutical company Intellipharmaceutics International Inc. and generic drug maker Par Pharmaceutical, Inc. have added the development and commercialization of additional strengths of generic Focalin XR (dexmethylphenidate hydrochloride) for the U.S. market to their existing agreement, which includes 5, 10, 15 and 20mg strengths of generic Focalin XR.

Under the new agreement, Intellipharmaceutics will receive an immediate cash payment from Par and will continue to receive a share of sales profits. Focalin XR is used in the treatment of Attention Deficit Hyperactivity Disorder. Sales in the U.S. were approximately $536 million for the year ending June 2011.

Intellipharmaceutics has five strengths (5, 10, 15, 20 and 30mg) of the generic Focalin XR pending with